This website is intended for Australian healthcare professionals.
Updates in the adjuvant treatment landscape in
high-risk MIUC after radical resection
The treatment landscape for high-risk MIUC following radical resection has continued to evolve with adjuvant immunotherapy becoming an available option.1
Neoadjuvant treatment choices can
impact adjuvant treatment options.
Has your MDT discussed all options?
Learn more about these changes and what this means for your practice:
See what's new
A quick summary to understand recent changes
Hear from the experts
Hear from international urology and medical oncology experts as they discuss multidisciplinary collaboration in MIUC decision-making and the role of adjuvant therapy in eligible patients
Stay up to date
Review the latest clinical data for adjuvant immunotherapy in high-risk MIUC following radical resection
This website is for Australian healthcare professionals only. If you are a patient or a member of the general public, please speak with your doctor.
MDT = multidisciplinary team; MIUC = muscle invasive urothelial cancer.
References: 1. Pharmaceutical Benefits Scheme (www.pbs.gov.au).
This website is intended for Australian Healthcare Professionals.
© 2024 Bristol-Myers Squibb. BMS Medical Information: 1800 067 567. Bristol-Myers Squibb Australia Pty Ltd, ABN 33 004 333 322, 4 Nexus Court, Mulgrave, VIC 3160. 1506-AU-2400260. August 2024. BRMSOY0225.
